目的:分析肺表面活性物质用于新生儿呼吸窘迫综合征中的临床效果。方法:选取62例新生儿为研究对象。结果:实验组31例患儿中,1例脑室内出血,2例支气管肺发育不良,3例早产儿视网膜病,1例死亡,住院平均天数11.5天。对照组31例患儿中4例脑室内出血,2例支气管肺发育不良,4例早产儿视网膜病,7例死亡,住院平均天数21.3天。2组患儿脑室内出血、早产儿视网膜病、死亡例数及住院天数对比差异明显,具有统计学意义(P<0.05);2组患儿支气管肺发育不良对比差异不明显,不具有统计学意义(P>0.05)。结论:对于有呼吸窘迫综合征的新生儿产后应给予密切监护,及早应用肺表面活性物质,可有效提高新生儿成活率,降低并发症发生率。 Objective: To analyze the clinical effect of pulmonary surfactant in neonatal respiratory distress syndrome. Methods: 62 newborns were selected as the research object. Results: Among the 31 children in the experimental group, 1 had intracerebral hemorrhage, 2 had bronchopulmonary dysplasia, 3 had retinopathy of prematurity, 1 died, and the average number of hospital days was 11.5. Among the 31 children in the control group, 4 had intracerebral hemorrhage, 2 had bronchopulmonary dysplasia, 4 had retinopathy of prematurity, 7 died, and the average number of days hospitalized was 21.3 days. There was significant difference between the two groups in children with intraventricular hemorrhage, retinopathy of prematurity, the number of deaths and days of hospitalization, with statistical significance (P <0.05). There was no significant difference in bronchopulmonary dysplasia between the two groups (P> 0.05). CONCLUSIONS: Neonates with respiratory distress syndrome should be closely monitored after delivery, and the early application of pulmonary surfactant can effectively improve neonatal survival rate and reduce the incidence of complications.